Latest news with #STING
Cision Canada
11 hours ago
- Business
- Cision Canada
Curadev Expands Strategic Collaboration for CRD3874-SI Through MSK Therapeutics Accelerator Program
BOSTON, June 10, 2025 /CNW/ -- Curadev Pharma, Inc., a clinical-stage biotechnology company developing novel immuno-oncology therapeutics, and Memorial Sloan Kettering Cancer Center (MSK), a world-leading cancer research and treatment institution, are expanding their collaboration through the MSK Therapeutics Accelerator program to advance the development of Curadev's small-molecule allosteric Stimulator of Interferon Genes (STING) agonist, CRD3874-SI, to be delivered systemically to patients with advanced/metastatic cancer. The collaboration builds on the ongoing Phase 1a/b dose escalation and expansion clinical trial (NCT06021626) currently underway at MSK for sarcoma and Merkel cell carcinoma patients, and aims to explore the potential of CRD3874-SI in treating additional types of cancer. Through the MSK Therapeutics Accelerator program, MSK will provide Curadev with expertise and institutional resources, including medical, clinical, and regulatory advice, to further the development of CRD3874-SI. This expanded collaboration marks a significant milestone in translating promising STING pathway research into broader clinical application and will be overseen by William Tap, MD, Chief of the Sarcoma Medical Oncology Service at MSK, and Ciara Kelly, MBBCh BAO, Interim Clinical Director of MSK's Sarcoma Oncology Service. Dr. William Tap said, "MSK and its Division of Solid Tumors are excited to co-develop CRD3874-SI, a novel first-in-class allosteric STING agonist, with Curadev. CRD3874-SI has demonstrated an encouraging safety and efficacy profile in a first-in-human study at MSK. CRD3874-SI is moving forward into multiple solid-tumor expansion cohorts, guided by disease specific experts and the support and structure of the MSK Accelerator Program, which is designed to enhance and expedite the development of novel compounds across malignancies. CRD3874-SI has the potential to offer patients a new treatment option with continued innovation and exploration of the benefits of immunotherapy in cancer care." Dr. Arjun Surya, Co-founder and CEO of Curadev, added, "We are encouraged by the early readouts with CRD3874-SI systemic monotherapy from our ongoing clinical trial in patients with treatment refractory cancers at MSK and are honored by the opportunity to deepen our collaboration through the MSK Therapeutics Accelerator program. The research and development collaboration between oncologists at MSK and the inventors of CRD3874-SI at Curadev could become a role model for advancing bench to bedside medicines. MSK's historic leadership position in the development of cancer immunotherapy and the exemplary dedication of the oncologists we work with is inspiring and make it an ideal partner in Curadev's effort to investigate the therapeutic potential of its systemically administered allosteric STING agonist in patients with advanced/metastatic cancer." About Curadev Curadev is a clinical-stage biotechnology company dedicated to discovering and developing novel small-molecule therapeutics for treating intractable diseases. Curadev has built an impressive portfolio of discovery research programs using a target-centric approach, innovative screening schemes, and traditional wet-lab chemistry and pharmacology, resulting in patent-protected drug candidates that modulate next-generation drug targets. Curadev Pharma, Inc., the US-based clinical development subsidiary founded in 2021, is currently leading the Phase1/2 trials of STING agonist assets under a US FDA-approved IND application. For more information, visit MSK's Therapeutics Accelerator program is a strategic partnership program between MSK and biotechnology companies to advance novel cancer therapeutics through all stages of drug development. The program brings together innovative healthcare companies with MSK's community of clinical and scientific experts to establish groundbreaking collaborations that can have a tangible impact on the treatment or management of cancer.
Yahoo
15-04-2025
- Politics
- Yahoo
Ukraine unveils its own Russian drone killer as U.S. backing wanes
Amid concern in Kyiv that the United States is becoming a less dependable ally, Ukraine has unveiled its own domestically developed drone designed specifically to counter one of Moscow's weapons of choice, Iranian-made Shahed explosive drones. Russia again launched multiple drones on Monday at Ukraine's Sumy region. Explosions rang out from strikes that claimed lives and damaged civilian infrastructure. Vladimir Putin's forces have used the lethal, relatively inexpensive Shahed drones to attack Ukraine's infrastructure for years. Last week, Ukrainian President Volodymyr Zelenskyy and visiting Belgian Prime Minister Bart de Wever met representatives of defense companies in Ukraine's capital Kyiv, where the new Ukrainian weapon system was revealed. Video posted by Zelenskyy on social media showed what was touted as a newly developed interceptor drone, but the images were kept obscure to avoid divulging details of the system, and no information on it was provided. Developers claim the interceptors have already taken down more than 20 Shaheds over about two months. Wild Hornets, a Ukrainian non-profit organization, is one of the entities behind the development of new interceptor drones. A co-founder of the group told CBS News that the interceptors it's working on, a system known as STING, went into production at the beginning of the year and are now being supplied in significant numbers to the Ukrainian Armed Forces. The organization, which said it's funded largely by private donations like other such groups backing Ukraine's war efforts, claims the interceptors, which it is still developing, can easily reach speeds over 125 miles per hour. Wild Hornets' spokesperson said the group imports many of the components needed to build the STING drones from China, as the European Union currently does "not have similar components of the appropriate quantity and quality." The organization emphasized that it was looking for ways to substitute Chinese components with Ukrainian-made parts. The spokesperson told CBS News that Wild Hornets' production of STING interceptors has been increasing by "several times" every month. Shortly after the weapons system was shown off for Zelenskyy, de Wever and the defense executives in Kyiv last week, Ukrainian and Belgian representatives signed a cooperation agreement between the countries' respective defense industries. Zelenskyy emphasized the importance of joint production to the "future security of all Europe." The importance of stopping Russia's exploding drones The new interceptors could prove vital for Ukraine. They offer a far cheaper and more sustainable option for taking down Russia's relatively small but multitudinous exploding drones compared to traditional air defense systems, which require more expensive anti-aircraft missiles, often supplied by Ukraine's partners. Kyiv has prioritized the development of such domestic technology in a bid to reduce its dependence on missile systems supplied by its Western allies. In a recent interview with a Ukrainian news outlet, Gen. Oleksandr Syrskyi, the commander-in-chief of Ukraine's military, said there had already been a reduction in U.S. support, while touting his country's innovation and growing defense production capacity. "The assistance from the United States has decreased. And the main assistance comes from our partners in Europe," Syrskyi told the LB (Left Bank) news outlet in an interview published on April 9. "But we must also rely on our own strength. And we have successes in the production of artillery. Quite significant successes in electronic warfare. We are making progress — our partners are already studying our experience." Moscow has used the Shahed drones to relentlessly target Ukraine's civil, energy and transport infrastructure. Despite a suspected targeting success rate of only about 10%, according to the U.S.-based Center for Strategic and International Studies, the Shahed's harder-to-detect, low altitude operation and cost of only about $35,000 per unit has made them a weapon of choice for Russia. CSIS notes that a single Russian Kalibr cruise missile, by comparison, costs over a million dollars. Even though Ukraine shoots down a majority of the Shaheds launched by Russia, they still pose a significant threat to the country. Shaheds launched by Russia at Ukraine's second-largest city, Kharkiv, killed two people and wounded more than a dozen others last month alone. A report issued in March by the Washington, D.C.-based Institute for Science and International Security said that over the course of seven months, Russia launched some 15,000 Shahed-type unmanned aerial vehicles at Ukraine. Russia started using the Iranian-designed Shaheds in August 2022, six months after Putin ordered his military's full-scale invasion of Ukraine. Savannah Bananas pack stadiums with their zany twist on baseball | 60 Minutes Watch: Blue Origin's first all-women flight crew launches to space What's at stake for Meta as Mark Zuckerberg testifies at antitrust trial
CBS News
15-04-2025
- Politics
- CBS News
Weary of waning U.S. support, Ukraine reveals domestically produced Russian drone interceptor
Amid concern in Kyiv that the United States is becoming a less dependable ally, Ukraine has unveiled its own domestically developed drone designed specifically to counter one of Moscow's weapons of choice, Iranian-made Shahed explosive drones. Russia again launched multiple drones on Monday at Ukraine's Sumy region. Explosions rang out from strikes that claimed lives and damaged civilian infrastructure. Vladimir Putin's forces have used the lethal, relatively inexpensive Shahed drones to attack Ukraine's infrastructure for years. Last week, Ukrainian President Volodymyr Zelenskyy and visiting Belgian Prime Minister Bart de Wever met representatives of defense companies in Ukraine's capital Kyiv, where the new Ukrainian weapon system was revealed. Video posted by Zelenskyy on social media showed what was touted as a newly developed interceptor drone, but the images were kept obscure to avoid divulging details of the system, and no information on it was provided. Developers claim the interceptors have already taken down more than 20 Shaheds over about two months. Wild Hornets, a Ukrainian non-profit organization, is one of the entities behind the development of new interceptor drones. A co-founder of the group told CBS News that the interceptors it's working on, a system known as STING, went into production at the beginning of the year and are now being supplied in significant numbers to the Ukrainian Armed Forces. The organization, which said it's funded largely by private donations like other such groups backing Ukraine's war efforts , claims the interceptors, which it is still developing, can easily reach speeds over 125 miles per hour. Wild Hornets' spokesperson said the group imports many of the components needed to build the STING drones from China, as the European Union currently does "not have similar components of the appropriate quantity and quality." The organization emphasized that it was looking for ways to substitute Chinese components with Ukrainian-made parts. The spokesperson told CBS News that Wild Hornets' production of STING interceptors has been increasing by "several times" every month. Shortly after the weapons system was shown off for Zelenskyy, de Wever and the defense executives in Kyiv last week, Ukrainian and Belgian representatives signed a cooperation agreement between the countries' respective defense industries. Zelenskyy emphasized the importance of joint production to the "future security of all Europe." The new interceptors could prove vital for Ukraine. They offer a far cheaper and more sustainable option for taking down Russia's relatively small but multitudinous exploding drones compared to traditional air defense systems, which require more expensive anti-aircraft missiles, often supplied by Ukraine's partners. Kyiv has prioritized the development of such domestic technology in a bid to reduce its dependence on missile systems supplied by its Western allies. In a recent interview with a Ukrainian news outlet, Gen. Oleksandr Syrskyi, the commander-in-chief of Ukraine's military, said there had already been a reduction in U.S. support, while touting his country's innovation and growing defense production capacity. "The assistance from the United States has decreased. And the main assistance comes from our partners in Europe," Syrskyi told the LB (Left Bank) news outlet in an interview published on April 9. "But we must also rely on our own strength. And we have successes in the production of artillery. Quite significant successes in electronic warfare. We are making progress — our partners are already studying our experience." Moscow has used the Shahed drones to relentlessly target Ukraine's civil, energy and transport infrastructure. Despite a suspected targeting success rate of only about 10%, according to the U.S.-based Center for Strategic and International Studies, the Shahed's harder-to-detect, low altitude operation and cost of only about $35,000 per unit has made them a weapon of choice for Russia. CSIS notes that a single Russian Kalibr cruise missile, by comparison, costs over a million dollars. Even though Ukraine shoots down a majority of the Shaheds launched by Russia, they still pose a significant threat to the country. Shaheds launched by Russia at Ukraine's second-largest city, Kharkiv, killed two people and wounded more than a dozen others last month alone. A report issued in March by the Washington, D.C.-based Institute for Science and International Security said that over the course of seven months, Russia launched some 15,000 Shahed-type unmanned aerial vehicles at Ukraine. Russia started using the Iranian-designed Shaheds in August 2022, six months after Putin ordered his military's full-scale invasion of Ukraine.
Jordan News
25-03-2025
- Health
- Jordan News
Revolutionary Discovery Opens the Door to New Treatments for COVID-19 and Alzheimer's - Jordan News
Scientists have made a groundbreaking discovery in understanding autoimmune diseases, potentially opening the door to new treatments for conditions like COVID-19 and Alzheimer's disease. اضافة اعلان Researchers from the University of Washington and the University of Pennsylvania have made a scientific breakthrough that could change the future of medicine by unveiling the protein ArfGAP2, which plays a crucial role in regulating immune responses. This important discovery came by chance while studying a rare disease known as vascular inflammation associated with the Stimulator of Interferon Genes (STING) protein, which affects one child in every million and causes the immune system to attack healthy tissues, especially in the lungs and extremities. This disease is often fatal before reaching adulthood, resulting from excessive activity of the STING protein, which is supposed to help the body detect viral DNA and trigger immune responses. However, in cases of vascular inflammation associated with STING, this protein remains constantly active, leading to chronic immune responses and tissue damage. The scientists found that this protein acts as a critical link between immune system activation and the release of inflammatory substances. Through a series of precise experiments, the research team demonstrated that disabling this protein in mice with vascular inflammation associated with STING completely halted tissue damage, potentially paving the way for developing new treatments for autoimmune diseases. What's even more exciting is that these results could extend to common diseases like COVID-19 and Alzheimer's, where inflammation plays a key role in their development. To explain how it works, the researchers used a powerful analogy, describing the discovered protein as the "traffic controller at a train station," which regulates the release of "trains" (inflammatory substances) from immune cells. Without this controller, the harmful inflammatory process halts while preserving beneficial immune functions. This new understanding represents a significant shift in immunology, as it provides the long-missing link in understanding how the immune system shifts from being a protector to attacking the body itself. Currently, the team is working on developing drug molecules that specifically target this protein, with clinical trials expected to begin within the next three years. If successful, these efforts could spark a real revolution in the treatment of a wide range of diseases affecting millions worldwide, from rheumatoid arthritis to multiple sclerosis, and potentially even some neurodegenerative diseases.
